Citation: Chanqi Ye, Jia Zhang, Jie Shen, Ruyin Chen, Qiong Li, Peng Zhao, Dong Chen, Jian Ruan. Attractive Pickering emulsion gel loaded with oxaliplatin and lactate dehydrogenase inhibitor increases the anti-tumor effect in hepatocellular carcinoma[J]. Chinese Chemical Letters, ;2025, 36(7): 110519. doi: 10.1016/j.cclet.2024.110519 shu

Attractive Pickering emulsion gel loaded with oxaliplatin and lactate dehydrogenase inhibitor increases the anti-tumor effect in hepatocellular carcinoma

Chanqi Ye ^{a, 1} ,
Jia Zhang ^{a, b, 1} ,
Jie Shen ^{a, 1} ,
Ruyin Chen ^{a, 1} ,
Qiong Li ^a ,
Peng Zhao ^{a, *,} ,
Dong Chen ^{a, b, *,} ,
Jian Ruan ^{a, *,}

a.
Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, and Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, Hangzhou 310003, China
b.
College of Energy Engineering and State Key Laboratory of Clean Energy Utilization, Zhejiang University, Hangzhou 310003, China

zhaop@zju.edu.cn

chen_dong@zju.edu.cn

software233@zju.edu.cn

Received Date: 15 April 2024
Revised Date: 28 September 2024
Accepted Date: 29 September 2024
Available Online: 30 September 2024

Figures(7)

Oxaliplatin (OXA) can be used as a palliative treatment for advanced hepatocellular carcinoma (HCC). While most patients still have rapid disease progression after OXA due to the drug resistance. The lactate dehydrogenase A (LDHA) inhibitors can reduce the inflammation-induced effects, metastasis, and proliferation potential of cancer cells. Here, we adopt the water-in-oil attractive Pickering emulsion gel (APEG) to deliver OXA and LDHA inhibitor, GSK2837808A (GSK). OXA is dissolved in water and GSK is dissolved in iodized oil. This drugs-loaded APEG has good biocompatibility and can release OXA and GSK slowly. OXA + GSK@gel has significant anti-tumor effect on HCC model, which can effectively inhibit tumor cell proliferation and promote tumor cell apoptosis. Meanwhile, flow analysis confirm that it could activate the tumor immune microenvironment in HCC. The infiltration of CD8⁺ T cells is increased, thereby providing better anti-tumor effect. The results suggest that the APEGs loaded with OXA and GSK can effectively improve the delivery efficiency and enhance the anti-tumor therapy.
- Anti-tumor therapy,
- Drug delivery,
- Immune activation,
- Oxaliplatin,
- Lactate dehydrogenase A
1. [1]
  H. Sung, J. Ferlay, R.L. Siegel, et al., CA Cancer J. Clin. 71 (2021) 209–249. doi: 10.3322/caac.21660
2. [2]
  D. Tang, S. Dong, N. Ma, et al., Hepatology. 51 (2010) 1255–1263. doi: 10.1002/hep.23451
3. [3]
  A. Benson, M. D'Angelica, D. Abbott, et al., J. Natl. Compr. Canc. Netw. 19 (2021) 541–565. doi: 10.6004/jnccn.2021.0022
4. [4]
  H. Zhu, Y. Shan, K. Ge, et al., Cell. Oncol. 43 (2020) 1203–1214. doi: 10.1007/s13402-020-00552-2
5. [5]
  R. Dhanasekaran, Semin. Liver Dis. 41 (2021) 9–18.
6. [6]
  J. Sheng, J. Wu, X. Yin, et al., Chin. Chem. Lett. 34 (2023) 107738.
7. [7]
  S.Y. Kim, Arch. Pharm. Res. 38 (2015) 299–301.
8. [8]
  E.L. Pearce, E.J. Pearce, Immunity 38 (2013) 633–643.
9. [9]
  S. Ganapathy-Kanniappan, J.F. Geschwind, et al., Mol. Cancer 12 (2013) 152. doi: 10.1186/1476-4598-12-152
10. [10]
  V.L. Payen, E. Mina, V.F. Van Hée, et al., Mol. Metab. 33 (2020) 48–66.
11. [11]
  M.J. Watson, P.D.A. Vignali, S.J. Mullett, et al., Nature 591 (2021) 645–651. doi: 10.1038/s41586-020-03045-2
12. [12]
  M.M.G. Kes, J. Van den Bossche, A.W. Griffioen, et al., Biochim. Biophys. Acta Rev. Cancer 1874 (2020) 188427.
13. [13]
  P. Sonveaux, F. Végran, T. Schroeder, et al., J. Clin. Invest. 118 (2008) 3930–3942.
14. [14]
  I. San-Millán, G.A. Brooks, Carcinogenesis 38 (2017) 119–133.
15. [15]
  S. Walenta, M. Wetterling, M. Lehrke, et al., Cancer Res. 60 (2000) 916–921.
16. [16]
  G. Bononi, S. Masoni, V. Di Bussolo, et al., Semin. Cancer Biol. 86 (2022) 325–333.
17. [17]
  Z.H. Wang, W.B. Peng, P. Zhang, et al., EBioMedicine 73 (2021) 103627.
18. [18]
  F. Khan, Y. Lin, H. Ali, et al., Nat. Commun. 15 (2024) 1987.
19. [19]
  P. Miao, S. Sheng, X. Sun, et al., IUBMB life 65 (2013) 904–910. doi: 10.1002/iub.1216
20. [20]
  V. Jurisic, S. Radenkovic, G. Konjevic, et al., Adv. Exp. Med. Biol. 867 (2015) 115–124. doi: 10.1007/978-94-017-7215-0_8
21. [21]
  V.R. Fantin, J. St-Pierre, P. Leder, Cancer Cell 9 (2006) 425–434.
22. [22]
  M. Koukourakis, A. Tsolou, S. Pouliliou, et al., Biochem. Biophys. Res. Commun. 491 (2017) 932–938.
23. [23]
  S Kim, H Lee, B Jeong, Carbohydr. Polym. 291 (2022) 119559.
24. [24]
  L. Zhai, Y. Shi, Y. Yan, et al., Chin. Chem. Lett. 34 (2023) 108104.
25. [25]
  H. Sun, H. Zhao, R. Yin, et al., Chin. Chem. Lett. 36 (2025) 110067. doi: 10.1016/j.cclet.2024.110067
26. [26]
  S.A. Mortazavi, R. Aboofazeli, Iran. J. Pharm. Res. 2 (2003) 135–140.
27. [27]
  A. Joseph, J. Pharm. Sci. 79 (1990) 1044.
28. [28]
  M. Talat, M. Zaman, R. Khan, et al., Drug Dev. Ind. Pharm. 47 (2021) 1193–1199. doi: 10.1080/03639045.2021.1993889
29. [29]
  X. Dai, J. Zhang, X. Bao, et al., Adv. Mater. 35 (2023) e2303542.
30. [30]
  B. Wu, C. Yang, Q. Xin, et al., Adv. Mater. 33 (2021) e2102362.
31. [31]
  R. Donne, A. Lujambio, Hepatology 77 (2023) 1773–1796. doi: 10.1002/hep.32740
32. [32]
  Y.X. Zhang, Y.Y. Zhao, J. Shen, et al., Nano Lett. 19 (2019) 2774–2783. doi: 10.1021/acs.nanolett.8b04296
33. [33]
  Y. Ma, C. Guo, X. Wang, et al., J. Exp. Clin. Cancer Res. 42 (2023) 237. doi: 10.2186/jpr.jpr_d_23_00098
34. [34]
  S. Qin, Y. Bai, H.Y. Lim, et al., J. Clin. Oncol. 31 (2013) 3501–3508.
35. [35]
  X. Yin, B. Tang, J.H. Li, et al., J. Exp. Clin. Cancer Res. 36 (2017) 166.
36. [36]
  L. Goyal, H. Zheng, T.A. Abrams, et al., Clin. Cancer Res. 25 (2019) 80–89. doi: 10.1158/1078-0432.ccr-18-0847
37. [37]
  J. Ding, J.E. Karp, A. Emadi, Cancer Biomark. 19 (2017) 353–363.
38. [38]
  A.X. Zhu, L.S. Blaszkowsky, D.P. Ryan, et al., J. Clin. Oncol. 24 (2006) 1898–1903.
39. [39]
  F. Li, X. Zheng, X. Wang, et al., Transl. Oncol. 14 (2021) 101202.
40. [40]
  S.J. Park, S. Kweon, M.K. Moyo, et al., Biomaterials 310 (2024) 122625.
41. [41]
  E. Limagne, M. Thibaudin, L. Nuttin, et al., Cancer Immunol. Res. 7 (2019) 1958–1969. doi: 10.1158/2326-6066.cir-19-0228
42. [42]
  K. Singer, M. Kastenberger, E. Gottfried, et al., Int. J. Cancer 128 (2011) 2085–2095. doi: 10.1002/ijc.25543
43. [43]
  Z. Husain, Y. Huang, P. Seth, et al., J. Immunol. 191 (2013) 1486–1495. doi: 10.4049/jimmunol.1202702
44. [44]
  J. Yan, W. Li, H. Tian, et al., ACS Nano 17 (2023) 14667–14677. doi: 10.1021/acsnano.3c02428
45. [45]
  M. Zhou, Y. Zhao, Y. Ding, et al., Mol. Cancer 9 (2010) 33.
46. [46]
  L. Hu, S. Huang, G. Chen, et al., ACS Appl. Mater. Interfaces 14 (2022) 31625–31633. doi: 10.1021/acsami.2c05841
1. [1]
  Wenjia Wang , Xingyue He , Xiaojie Wang , Tiantian Zhao , Osamu Muraoka , Genzoh Tanabe , Weijia Xie , Tianjiao Zhou , Lei Xing , Qingri Jin , Hulin Jiang . Glutathione-depleted cyclodextrin pseudo-polyrotaxane nanoparticles for anti-inflammatory oxaliplatin (Ⅳ) prodrug delivery and enhanced colorectal cancer therapy. Chinese Chemical Letters, 2024, 35(4): 108656-. doi: 10.1016/j.cclet.2023.108656
2. [2]
  Jiaqi Huang , Renjiang Kong , Yanmei Li , Ni Yan , Yeyang Wu , Ziwen Qiu , Zhenming Lu , Xiaona Rao , Shiying Li , Hong Cheng . Feedback enhanced tumor targeting delivery of albumin-based nanomedicine to amplify photodynamic therapy by regulating AMPK signaling and inhibiting GSTs. Chinese Chemical Letters, 2024, 35(8): 109254-. doi: 10.1016/j.cclet.2023.109254
3. [3]
  Jin Wang , Xiaoyan Pan , Junyu Zhang , Qingqing Zhang , Yanchen Li , Weiwei Guo , Jie Zhang . Active molecule-based theranostic agents for tumor vasculature normalization and antitumor efficacy. Chinese Chemical Letters, 2024, 35(8): 109187-. doi: 10.1016/j.cclet.2023.109187
4. [4]
  Linghui Zou , Meng Cheng , Kaili Hu , Jianfang Feng , Liangxing Tu . Vesicular drug delivery systems for oral absorption enhancement. Chinese Chemical Letters, 2024, 35(7): 109129-. doi: 10.1016/j.cclet.2023.109129
5. [5]
  Zhilong Xie , Guohui Zhang , Ya Meng , Yefei Tong , Jian Deng , Honghui Li , Qingqing Ma , Shisong Han , Wenjun Ni . A natural nano-platform: Advances in drug delivery system with recombinant high-density lipoprotein. Chinese Chemical Letters, 2024, 35(11): 109584-. doi: 10.1016/j.cclet.2024.109584
6. [6]
  Mengwei Ye , Qingqing Xu , Huanhuan Jian , Yiduo Ding , Wenpeng Zhao , Chenxiao Wang , Junya Lu , Shuaipeng Feng , Siling Wang , Qinfu Zhao . Recent trends of biodegradable mesoporous silica based nanoplatforms for enhanced tumor theranostics. Chinese Chemical Letters, 2025, 36(6): 110221-. doi: 10.1016/j.cclet.2024.110221
7. [7]
  Han Wu , Yumei Wang , Zekai Ren , Hailin Cong , Youqing Shen , Bing Yu . The nanocarrier strategy for crossing the blood-brain barrier in glioma therapy. Chinese Chemical Letters, 2025, 36(4): 109996-. doi: 10.1016/j.cclet.2024.109996
8. [8]
  Xingqun Pu , Rongrong Liu , Yuting Xie , Chenjing Yang , Jingyi Chen , Baoling Guo , Chun-Xia Zhao , Peng Zhao , Jian Ruan , Fangfu Ye , David A Weitz , Dong Chen . One-step preparation of biocompatible amphiphilic dimer nanoparticles with tunable particle morphology and surface property for interface stabilization and drug delivery. Chinese Chemical Letters, 2025, 36(3): 109820-. doi: 10.1016/j.cclet.2024.109820
9. [9]
  Yuanzheng Wang , Chen Zhang , Shuyan Han , Xiaoli Kong , Changyun Quan , Jun Wu , Wei Zhang . Cancer cell membrane camouflaged biomimetic gelatin-based nanogel for tumor inhibition. Chinese Chemical Letters, 2024, 35(11): 109578-. doi: 10.1016/j.cclet.2024.109578
10. [10]
  Makhloufi Zoulikha , Zhongjian Chen , Jun Wu , Wei He . Approved delivery strategies for biopharmaceuticals. Chinese Chemical Letters, 2025, 36(2): 110225-. doi: 10.1016/j.cclet.2024.110225
11. [11]
  Jing Zhang , Charles Wang , Yaoyao Zhang , Haining Xia , Yujuan Wang , Kun Ma , Junfeng Wang . Application of magnetotactic bacteria as engineering microrobots: Higher delivery efficiency of antitumor medicine. Chinese Chemical Letters, 2024, 35(10): 109420-. doi: 10.1016/j.cclet.2023.109420
12. [12]
  Tong Tong , Lezong Chen , Siying Wu , Zhong Cao , Yuanbin Song , Jun Wu . Establishment of a leucine-based poly(ester amide)s library with self-anticancer effect as nano-drug carrier for colorectal cancer treatment. Chinese Chemical Letters, 2024, 35(12): 109689-. doi: 10.1016/j.cclet.2024.109689
13. [13]
  Lihang Wang , Mary Li Javier , Chunshan Luo , Tingsheng Lu , Shudan Yao , Bing Qiu , Yun Wang , Yunfeng Lin . Research advances of tetrahedral framework nucleic acid-based systems in biomedicine. Chinese Chemical Letters, 2024, 35(11): 109591-. doi: 10.1016/j.cclet.2024.109591
14. [14]
  Yong-Dan Zhao , Yidan Wang , Rongrong Wang , Lina Chen , Hengtong Zuo , Xi Wang , Jihong Qiang , Geng Wang , Qingxia Li , Canqi Ping , Shuqiu Zhang , Hao Wang . Reversing artemisinin resistance by leveraging thermo-responsive nanoplatform to downregulating GSH. Chinese Chemical Letters, 2024, 35(6): 108929-. doi: 10.1016/j.cclet.2023.108929
15. [15]
  Keyang Li , Yanan Wang , Yatao Xu , Guohua Shi , Sixian Wei , Xue Zhang , Baomei Zhang , Qiang Jia , Huanhua Xu , Liangmin Yu , Jun Wu , Zhiyu He . Flash nanocomplexation (FNC): A new microvolume mixing method for nanomedicine formulation. Chinese Chemical Letters, 2024, 35(10): 109511-. doi: 10.1016/j.cclet.2024.109511
16. [16]
  Yinglan Yu , Sajid Hussain , Jianping Qi , Lei Luo , Xuemei Zhang . Mechanisms and applications: Cargos transport to basolateral membranes in polarized epithelial cells. Chinese Chemical Letters, 2024, 35(12): 109673-. doi: 10.1016/j.cclet.2024.109673
17. [17]
  Huijuan Zhang , Chenglin Liang , Xinyi Ding , Meng Zhang , Siyu Lu , Lin Hou . Manganese-based nano-delivery system for sensitized anti-tumor immunotherapy via combined autophagy inhibition. Chinese Chemical Letters, 2025, 36(7): 110525-. doi: 10.1016/j.cclet.2024.110525
18. [18]
  Ningyue Xu , Jun Wang , Lei Liu , Changyang Gong . Injectable hydrogel-based drug delivery systems for enhancing the efficacy of radiation therapy: A review of recent advances. Chinese Chemical Letters, 2024, 35(8): 109225-. doi: 10.1016/j.cclet.2023.109225
19. [19]
  Yi Cao , Xiaojiao Ge , Yuanyuan Wei , Lulu He , Aiguo Wu , Juan Li . Tumor microenvironment-activatable neuropeptide-drug conjugates enhanced tumor penetration and inhibition via multiple delivery pathways and calcium deposition. Chinese Chemical Letters, 2024, 35(4): 108672-. doi: 10.1016/j.cclet.2023.108672
20. [20]
  Jiechen Liu , Xiaoguang Li , Ruiyang Xia , Yuqi Wang , Fenghe Zhang , Yongzhi Pang , Qing Li . Efficient suppression of oral squamous cell carcinoma through spatial dimension conversion drug delivery systems-enabled immunomodulatory-photodynamic therapy. Chinese Chemical Letters, 2024, 35(12): 109619-. doi: 10.1016/j.cclet.2024.109619

Get Citation

PDF

XML

Metrics

PDF Downloads(0)
Abstract views(5)
HTML views(1)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142